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Metachromatic  leukodystrophy  (MLD)  is  an  autosomal 
recessive  lysosomal  storage  disorder  caused  by  a  defi-
ciency  of  arylsulphatase  A  (ARSA)  (EC  3.1.6.8).  MLD 
involves progressive demyelination, resulting in a variety 
of  neurological  symptoms  varying  in  severity  (Kolodny 
and  Fluharty,  1995).  The  ARSA  gene  consists  of  eight 
exons encoding the 507 amino acid enzyme (Stein et al, 
1989).  It is transcribed into three mRNA species, a major 
species of 2.1 kb, and two minor species of 3.7 and 4.8 kb.  
Over 90 largely  missense  mutations and polymorphisms 
have been identified in the ARSA gene (Human Gene Mu-
tation Database). Some healthy individuals, referred to as 
having pseudodeficiency of arylsulphatase A (ARSA-PD), 
have very low ARSA activity. The molecular defect re-
sponsible for ARSA-PD is characterised by two A to G 
transitions  (Gieselmann  et  al,  1989),  the  first  of  which 
causes the substitution of a glycosylated asparagine with a 
serine residue at position 350 (N350S), resulting in about 
50% of enzyme being mistargeted.  The second results in a 
non-functional polyadenylylation signal and a deficiency 
of the major 2.1 kb mRNA species, leading to a 70% re-
duction of polyadenylylated mRNA (Harvey et al, 1998).  
As  a  result  of  the  combined  effect  of  these  variants, 
ARSA-PD homozygotes have only about 10% of normal 
enzyme activity but this is sufficient to prevent the devel-
opment of MLD symptoms. 
 
The individual described in this study showed features of 
an MLD-like neuropathy and exhibited ARSA activity in 
the pseudodeficiency range.  He was found to be negative 
for all known MLD mutations, but heterozygous for the 
ARSA-PD allele.  To detect possible additional sequence 
alterations,  all  eight  exons  and  their  intron  boundaries 
were PCR amplified and subjected to single stranded con-
formational polymorphism (SSCP) analysis as previously 
described (Harvey et al, 1993). The exon 2 PCR product 
revealed  that  he  was  heterozygous  for  a  change  in  this 
exon  (Figure  1A).  Direct  sequence  analysis  revealed  an 
insertion of a single G nucleotide in a run of 7 G’s starting 
at  ARSA  cDNA  position  289,  resulting  in  a  frameshift 
mutation (289insG; Figure 1B). 
 
 
 
 
 
 
Figure 1. (A) SSCP analysis of exon 2 genomic PCR products.  
Tracks 2-4 are controls, track 1 is of the individual described in 
this study, and contains a band of altered conformation as indi-
cated.  (B) Reverse automated sequence analysis of the altered 
conformation products in a normal control (above) and the index 
case (below) showing an additional heterozygous ‘G” in a run of 
7 “G”’s as indicated. 
 
This frameshift mutation results in normal translation for 
99 amino acids followed by 31 aberrant amino acids prior 
to premature termination of the protein. Consequently, this 
mutation is likely to totally disrupt ARSA activity and can 
be considered a new null allele for MLD. 
 
The identity of the mutation was confirmed by allele spe-
cific oligonucleotide (ASO) analysis of 100 normal alleles, 
31 MLD alleles and 33 ARSA-PD alleles (using the follow- 
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ing ASO oligonucleotides: 289n, 5'-CCGGGGGGGCCTGC-3'; 
289insG,  5'-CCGGGGGGGGCCTG-3').  289insG  was  not 
present on any  of these alleles except in the index case 
described in this paper, who was heterozygous.  Further 
ASO  analysis  revealed  that  his  mother  carried  289insG 
and his father carried the ARSA-PD allele (Figure 2), ac-
counting  for  the  low  enzyme  activity  observed  in  both 
parents.  
 
 
 
Figure 2.  Duplicate filters containing exon 2 products were 
probed as indicated with the normal and mutant oligonucleotides 
for 289insG.  A control normal sample was included.  The pedi-
gree is as follows; grey represents the ARSA-PD allele, black; 
the 289insG mutation. Blood leukocyte activity of ARSA is 
measured in nmol/min/mg protein, with a normal reference range 
of 1.0 - 5.0.  The ARSA activities of the index case (0.45), his 
mother (1.3) and father (2.9) are indicated. 
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